[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337581-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337581-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","design-of-the-hpv-automated-visual-evaluation-pave-study-validating-a-novel-cervical-screening-strategy","Design of the HPV-automated visual evaluation (PAVE) study - Validating a novel cervical screening strategy","","The HPV-automated visual evaluation (PAVE) Study is a multinational initiative aiming to strengthen cervical cancer prevention in resource-constrained regions. The background highlights unequal access to preventive care and describes PAVE as a combined screening-triage-treatment approach integrating self-sampled HPV testing, deep-learning automated visual evaluation (AVE), and targeted therapies. Phase 1 evaluates hierarchical HPV assessment and risk scoring against histologic high-grade precancer while not yet using AVE results for patient management, contrasting with standard local care.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/design-of-the-hpv-automated-visual-evaluation-pave-study-validating-a-novel-cervical-screening-strategy/337581/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/design-of-the-hpv-automated-visual-evaluation-pave-study-validating-a-novel-cervical-screening-strategy/337581.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the primary goal of the PAVE Study?","Question",{"text":63,"@type":64},"To validate a novel screen-triage-treat strategy for cervical cancer prevention by integrating self-sampled HPV testing, AVE, and targeted therapies to improve accuracy and feasibility in resource-limited areas.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does Phase 1 screening work in the PAVE Study?",{"text":68,"@type":64},"Phase 1 screens up to 100,000 women aged 25–49 across nine countries using hierarchical self-collected vaginal samples for HPV evaluation, followed by additional assessments for HPV-positive participants including pelvic exams, cervical imaging, and biopsies.",{"name":70,"@type":61,"acceptedAnswer":71},"How are AVE results handled in Phase 1?",{"text":72,"@type":64},"AVE algorithms analyze images to assign precancer risk scores, validated against histologic high-grade precancer; however, Phase 1 does not integrate AVE results into patient management and contrasts them with local standard care.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337581,1791247281,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":33,"preview_urls":144},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","TOOLS AND RESOURCES  \n*For correspondence:  \n[desanjose.silvia@gmail.com](desanjose.silvia@gmail.com)[ ](desanjose.silvia@gmail.com)[Competing interest:](Competing interest: See page)[ See page](Competing interest: See page)[ ](Competing interest: See page)15  \nFunding: See page 15  \nSent for Review  \n17 August 2023  \nPreprint posted  \n31 August 2023  \nReviewed preprint posted  \n16 October 2023  \nReviewed preprint revised  \n05 December 2023  \nVersion of Record published  \n15 January 2024  \nReviewing Editor: Talía Malagón, McGill University, Canada  \n This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.  \nDesign of the HPV-automated visual evaluation (PAVE) study: Validating a novel cervical screening strategy  \nSilvia de Sanjosé1,2*, Rebecca B Perkins3, Nicole Campos4, Federica Inturrisi1, Didem Egemen1, Brian Befano5,6, Ana Cecilia Rodriguez1, Jose Jerónimo1, Li C Cheung1, Kanan Desai1, Paul Han7, Akiva P Novetsky8, Abigail Ukwuani1, Jenna Marcus9, Syed Rakin Ahmed10,11,12,13, Nicolas Wentzensen1,  \nJayashree Kalpathy-Cramer10,14, Mark Schiffman1, On behalf of the PAVE Study Group  \n1 Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, United States; 2 ISGlobal, Barcelona, Spain; 3 University Chobanian and Avedisian School of Medicine/Boston Medical Center, Boston, United States; 4Center for Health Decision Science, Harvard T. H. Chan School of Public Health, Boston, United States; 5 Information Management Services Inc, Calverton, United States; 6 Department of Epidemiology, University of Washington School of Public Health, Seattle, United States; 7 Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Rockville, United States; 8Westchester Medical Center/New York Medical College, Valhalla, United States; 9 Feinberg School of Medicine at Northwestern University, Chicago, United States; 10Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, United States; 11 Harvard Graduate Program in Biophysics, Harvard Medical School, Harvard University, Cambridge, United States; 12 Massachusetts Institute of Technology, Cambridge, United States; 13Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, United States; 14 University of Colorado Anschutz Medical Campus, Aurora, United States  \nAbstract  \nBackground: The HPV-automated visual evaluation (PAVE) Study is an extensive, multinational initiative designed to advance cervical cancer prevention in resource-constrained regions. Cervical cancer disproportionally affects regions with limited access to preventive measures. PAVE aims to assess a novel screening-triage-treatment strategy integrating self-sampled HPV testing, deep-learningbased automated visual evaluation (AVE), and targeted therapies.  \nMethods: Phase 1 efficacy involves screening up to 100,000 women aged 25–49 across nine countries, using self-collected vaginal samples for hierarchical HPV evaluation: HPV16, else HPV18/45, else HPV31/33/35/52/58, else HPV39/51/56/59/68 else negative. HPV-positive individuals undergo further evaluation, including pelvic exams, cervical imaging, and biopsies. AVE algorithms analyze images, assigning risk scores for precancer, validated against histologic high-grade precancer. Phase 1, however, does not integrate AVE results into patient management, contrasting them with local standard care.  \nde Sanjosé et al. eLife 2023;12:RP91469. DOI: [https://doi.org/10.7554/eLife.91469](https://doi.org/10.7554/eLife.91469) 1 of 20  \n Tools and resources Epidemiology and Global Health  \nPhase 2 effectiveness focuses on deploying AVE software and HPV genotype data in real-time clinical decision-making,","cbCaiiqVvVP7MZ9L","https://ap.wps.com/l/cbCaiiqVvVP7MZ9L","pdf",1249318,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Global burden of cervical cancer","[{\"question\":\"What is the primary goal of the PAVE Study?\",\"answer\":\"To validate a novel screen-triage-treat strategy for cervical cancer prevention by integrating self-sampled HPV testing, AVE, and targeted therapies to improve accuracy and feasibility in resource-limited areas.\"},{\"question\":\"How does Phase 1 screening work in the PAVE Study?\",\"answer\":\"Phase 1 screens up to 100,000 women aged 25–49 across nine countries using hierarchical self-collected vaginal samples for HPV evaluation, followed by additional assessments for HPV-positive participants including pelvic exams, cervical imaging, and biopsies.\"},{\"question\":\"How are AVE results handled in Phase 1?\",\"answer\":\"AVE algorithms analyze images to assign precancer risk scores, validated against histologic high-grade precancer; however, Phase 1 does not integrate AVE results into patient management and contrasts them with local standard care.\"}]","Design of the HPV-automated visual evaluation (PAVE) study - Validating a novel cervical screening strategy | PDF",1790019677,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0db799121df6eec5e521bdce8ec1871b.webp",983,1272,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9e8e1e0b7f27dd5f3428d4917d387ae.webp",982,1270,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2bb7db7f74fe7aaa6067567717f74a54.webp",981,1269,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d70d134db5c2d8bfdb77497a75db4aec.webp",980,1268]